Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

•SOF/VEL/VOX demonstrated excellent effectiveness in patients with HCV and previous DAA failure in a real-life study. •Cirrhosis (p = 0.005) and hepatocellular carcinoma onset (p = 0.02) were the only features associated with treatment failure. •Treatment failures (4%) occurred in patients with cirrhosis, with genotypes HCV-1a and 3 the most represented. Background & Aims Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for...